Bristol-Myers Squibb Company
ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

Last updated:

Abstract:

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Status:
Application
Type:

Utility

Filling date:

8 May 2020

Issue date:

14 Jan 2021